Enanta Pharmaceuticals (ENTA) Long-Term Investments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Long-Term Investments data on file, last reported at $63.2 million in Q1 2026.

• Quarterly Long-Term Investments changed N/A year-over-year to $63.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.2 million (changed N/A YoY) and the FY2022 annual result came in at $29.3 million, down 72.99% from the prior year.
• Long-Term Investments advanced to $63.2 million in Q1 2026, from $56.1 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $63.2 million in Q1 2026 to a low of $5.9 million in Q2 2023.
• A 5-year average of $35.6 million and a median of $39.4 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments slumped 84.97% — and 2024, when it surged 617.59%.
• Tracing ENTA's Long-Term Investments over 5 years: stood at $26.9 million in 2022, then sank by 78.01% to $5.9 million in 2023, then surged by 617.59% to $42.5 million in 2024, then jumped by 31.86% to $56.1 million in 2025, then increased by 12.81% to $63.2 million in 2026.
• The last three Long-Term Investments figures came in at $63.2 million (Q1 2026), $56.1 million (Q4 2025), and $42.5 million (Q2 2024), per Business Quant data.